ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Vor Biopharma Inc

Vor Biopharma Inc (VOR)

1.11
0.00
(0.00%)
Closed January 02 4:00PM
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
1.11
Bid
1.07
Ask
1.10
Volume
-
0.00 Day's Range 0.00
0.6354 52 Week Range 3.1399
Market Cap
Previous Close
1.11
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
656,592
Shares Outstanding
68,673,612
Dividend Yield
-
PE Ratio
-0.64
Earnings Per Share (EPS)
-1.72
Revenue
-
Net Profit
-117.86M

About Vor Biopharma Inc

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Vor Biopharma Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker VOR. The last closing price for Vor Biopharma was $1.11. Over the last year, Vor Biopharma shares have traded in a share price range of $ 0.6354 to $ 3.1399.

Vor Biopharma currently has 68,673,612 shares outstanding. The market capitalization of Vor Biopharma is $76.23 million. Vor Biopharma has a price to earnings ratio (PE ratio) of -0.64.

VOR Latest News

Vor Bio Announces $55.6 Million Private Placement

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with...

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue...

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and...

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meetingHan Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2427.58620689660.871.350.8224107771.22419856CS
40.219924.70508931580.89011.350.810164001.10592993CS
120.4363.23529411760.681.350.63546565920.95781437CS
260.1313.26530612240.981.350.63547154930.91980269CS
52-1.14-50.66666666672.253.13990.63545229361.18411817CS
156-10.56-90.488431876611.6712.730.63542652322.41841824CS
260-40.91-97.358400761542.0263.620.63542420016.23538325CS

VOR - Frequently Asked Questions (FAQ)

What is the current Vor Biopharma share price?
The current share price of Vor Biopharma is $ 1.11
How many Vor Biopharma shares are in issue?
Vor Biopharma has 68,673,612 shares in issue
What is the market cap of Vor Biopharma?
The market capitalisation of Vor Biopharma is USD 76.23M
What is the 1 year trading range for Vor Biopharma share price?
Vor Biopharma has traded in the range of $ 0.6354 to $ 3.1399 during the past year
What is the PE ratio of Vor Biopharma?
The price to earnings ratio of Vor Biopharma is -0.64
What is the reporting currency for Vor Biopharma?
Vor Biopharma reports financial results in USD
What is the latest annual profit for Vor Biopharma?
The latest annual profit of Vor Biopharma is USD -117.86M
What is the registered address of Vor Biopharma?
The registered address for Vor Biopharma is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Vor Biopharma website address?
The website address for Vor Biopharma is www.vorbio.com
Which industry sector does Vor Biopharma operate in?
Vor Biopharma operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
$ 17.43
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 69.0184
(0.00%)
0
AADIAadi Bioscience Inc
$ 3.155
(0.00%)
0
AACGATA Creativity Global
$ 0.846
(0.00%)
0
AALAmerican Airlines Group Inc
$ 17.43
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 69.0184
(0.00%)
0
AADIAadi Bioscience Inc
$ 3.155
(0.00%)
0
AACGATA Creativity Global
$ 0.846
(0.00%)
0
AALAmerican Airlines Group Inc
$ 17.43
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 69.0184
(0.00%)
0
AADIAadi Bioscience Inc
$ 3.155
(0.00%)
0
AACGATA Creativity Global
$ 0.846
(0.00%)
0

VOR Discussion

View Posts
Monksdream Monksdream 12 hours ago
VOR, ten day hourly
πŸ‘οΈ0
Monksdream Monksdream 12 hours ago
So it’s a CRSPR stock
Certainly when Jennifer Doudna and Emanelle Charpentier who won the 2020 chemistry Nobel wanted to share their discovery
Gene editing in many respects remains in the R&D stage
They require tons of money to continue research
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 13 hours ago
In good company:
"Under the deal, Vor Bio will issue 55.9 million common stock shares and corresponding warrants to buy an additional 69.8 million shares at a combined price of $0.99425 per share and warrant. The warrants, exercisable at $0.838 per share, might be used until 2031, hence perhaps adding $58.5 million in profits if completely used.

New investor Reid Hoffman spearheaded the fundraising with major shareholder RA Capital Management, Vor Bio. As agreed upon, each will get board representation. Hoffman called the company's trem-cel therapy which targets acute myeloid leukemia using CRISpen/Cas9 technology a hopeful development in cancer treatment."

https://en.wikipedia.org/wiki/Reid_Hoffman

https://finance.yahoo.com/news/vor-biopharma-secures-55-6m-142740239.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAG0tuNK9MvQB11zJKjsCQuEXY65q6qJMzVa2xMmGe_UPW73P3TlZrz53TlAto0KIOzFJ1VOTQl_6hH3osmqgEEGKEQk_aQUDk2rx8achcDajSgaiFx67nHkqOXSvZcVp8ESdlQrR50KKetBIcDD94B2WvRxwy_U_Dyng_1W8jD1d
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 5 days ago
close above 200??
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 6 days ago
Money goes where its treated best.... now imagine what the stock can do on actual data
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 6 days ago
not bad
still looking for a VINC move! waiting for the unveil
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 6 days ago
GOOD stuff - remember traded at .8s last weeks

Vor Bio will issue an aggregate of 55,871,260 shares of common stock and accompanying warrants to purchase an aggregate of 69,839,075 shares of common stock at a combined price of $0.99425 per share and accompanying warrants. The warrants will have a per share exercise price of $0.838 and may be exercised at any time on or after the closing date and through the seventh anniversary of the closing date
https://www.globenewswire.com/news-release/2024/12/27/3002259/0/en/Vor-Bio-Announces-55-6-Million-Private-Placement.html
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 2 weeks ago
beam me up scotty
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 2 weeks ago
readying here
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 2 months ago
VINC type move coming
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 2 months ago
super super undervalued. Sid Mukherjee - gifted founder. Couple with recent clinical validation...
Problem in AML is not the drugs efficacy rather the possibility to handle the drug. They might just fix that.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 2 months ago
good dip buy
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 4 months ago
The buyers of all these shares arent going anywhere. Waiting for it to unfold.
All the traders didnt understand this prudent PR? You dont need fluffy if you have the real deal
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 4 months ago
remember this was founded to heal patients, not retire the management. This is a mission by the brilliant founder and the $$ will come as a by product of things being very right.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 4 months ago
Helps where CAR T cant in AML. Its about giving MORE of the drugs that heal..... they work but the body cant handle them. With VOR, it can.

People might just start realizing how huge the possibilities for this are.... GIVEN: r/r AML makes up 40-50% in younger patients and the great majority of elderly patients.
Now experiment with the 20bn TAM for r/r AML and some funny numbers start popping up.
Look at the founder... hes onto something.

the actual data will speak soon. The investigator is ultra optimistic.... he likely saw more.
πŸ‘οΈ0
glenn1919 glenn1919 4 months ago
VOR................................https://stockcharts.com/h-sc/ui?s=VOR&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
VOR new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
VOR new 52 week low
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 6 months ago
Sid Mukherjee saw the potential in Saar Gills and Carl Junes approach and funded VOR==== shielding the right cells and attacking the cancer. For simplicity, it could be summed up as bottom up selectivity.................
Very different from all the other CAR T stuff out there that is pretty much top-down-y. And in my opinion, top down systems dont work.
5am and RA certainly think so. Will go back to the IPO price and then some is my bet.
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
GNPX new 52 week low

πŸ‘οΈ0
PonkenPlonken PonkenPlonken 6 months ago
Im starting to think someone just buys them out.
Interesting action yesterday.
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
VOR new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
VOR new 52 week low
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 7 months ago
elevated volume for quite some time now.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 8 months ago
https://en.wikipedia.org/wiki/Siddhartha_Mukherjee founder is a smart man. They can do Car T without the tox.
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
VORBunder $2
πŸ‘οΈ0
glenn1919 glenn1919 10 months ago
VOR.....................................https://stockcharts.com/h-sc/ui?s=VOR&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock